, and a mixture of 0-5 ml absolute alcohol and 0 5 ml contrast medium (iohexol) injected into the tumour. The sclerosant mixture filled the venous network of the tumour and rapidly abolished flow in the opacified vessels.
After the procedure the patient experienced a little discomfort in her left loin, which was controlled with mild analgesics, and a fever of 38'C subsided after three days without antibiotics. Labetalol and hydralazine were withdrawn and her blood pressure remained well controlled. She was discharged home taking spironolactone (200 mg daily) only, which was stopped six weeks later. Computed tomography six weeks after the procedure showed a reduction in tumour size, and a 75Se cholesterol scintiscan showed normal uptake on the right but no uptake in the left adrenal gland. Blood pressure and plasma aldosterone and plasma and urine electrolyte concentrations remained normal when she had stopped all drugs. Twelve months after tumour ablation the patient remained normokalaemic without spironolactone and had needed only a small dose of a 3 adrenoceptor antagonist (oxprenolol 40 mg twice daily) to control her blood pressure.
Comment
Conn's tumours are usually hypovascular4; this and the fact that the adrenal gland receives its arterial supply from at least three different sources mean that it is not feasible to embolise these tumours by the arterial route, the approach normally employed for tumour embolisa- Cyclosporin A nephrotoxicity related to changes in haemoglobin concentration Cyclosporin A is increasingly being used for patients undergoing bone marrow and solid organ grafting. Also preliminary results show that cyclosporin A may be of benefit in some autoimmune diseases, including primary biliary cirrhosis.' Of the side effects of cyclosporin A, nephrotoxicity is the most common; this is largely dose dependent and reversible,2 and with careful monitoring of cyclosporin concentrations in blood or plasma the frequency of the complication may be reduced.
We describe four patients with primary biliary cirrhosis receiving cyclosporin A in whom the development of nephrotoxicity was unexpected and shown to be related to a fall in haemoglobin concentration associated with a rise in plasma cyclosporin values.
Case histories
The four patients (two women; age range 56-63) had primary biliary cirrhosis at the cirrhotic stage diagnosed by liver biopsy. Serum bilirubin concentrations ranged from 25 to 98 jAmol/l (1-5 to 5-7 mg/100 ml) (median 60 jtmol/l (3-5 mg/100 ml); upper limit of normal 15 Mmol/l (0 9 mg/100 ml)).
All four were participating in a pilot study to determine a therapeutic and non-toxic dose of cyclosporin before a formal double blind, prospective controlled trial. The patients had normal renal function on admission to the study, as evidenced by normal serum creatinine and urea concentrations and creatinine clearance. Cyclosporin A (3 or 4 mg/kg/day) had been administered at a constant dose for at least three months before the occurrence of complications, and during this time the serum creatinine concentration had remained below 100 Zmol/l (1 1 mg/100 ml). Trough plasma concentrations of cyclosporin A, as measured by radioimmunoassay, were maintained in the therapeutic range below 200 Htg/l-a concentration that is effective in correcting the in vitro suppressor cell abnormalities of patients with primary biliary cirrhosis,3 although a little lower than that currently aimed at in prevention of graft rejection.
Subsequently, in association with a fall in haemoglobin concentration, there was a rise in serum creatinine and trough plasma cyclosporin A values (figure). In two cases falls in haemoglobin of 5-6 g/dl and 2-6 g/dl were due 250- Hoemoglobin (g/dl)
Relation between haemoglobin concentration and serum creatinine and plasma cyclosporin A concentrations in four patients with primary biliary cirrhosis receiving maintenance dose of cydosporin A.
Conversion: SI to traditional units-Greatinine: 10 jAmol/l0 -01 mg/100 ml.
to gastrointestinal haemorrhage, from varices and gastric erosions respectively. In the other two the haemoglobin concentration fell by 0-8 g/dl and 2-3 g/dl and the blood film showed a macrocytosis, which after investigation was attributed to chronic liver disease and myxoedema. In the two patients with blood loss the dose of cyclosporin A was maintained and correction of the anaemia by blood transfusion and iron supplements was accompanied by a return of serum creatinine and plasma cyclosporin A to previous values. In the other two the dose of cyclosporin A was reduced, with a concomitant fall in serum creatinine concentration. In all patients serum lipoprotein concentrations remained stable and normal throughout.
Comment
Cyclosporin A is extensively metabolised by the liver before being excreted into the bile and then undergoes enterohepatic circulation,' though results obtained to date at a dose of 5 mg/kg/day in patients with primary biliary cirrhosis show the pharmacokinetics and metabolism of cyclosporin to be similar to those in normal subjects (Robson et al, unpublished data) . In the blood cyclosporin A is bound predominantly to red cells (50%) and to a less extent leucocytes (20%); the remaining 30-40% of the drug is in the plasma, mostly bound to lipoproteins.5 In our patients we postulate that the rise in
